Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

William L. Hwang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4514-8837; OpenAlex author ID A5047708165; NIH RePORTER profile ID 10675977. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 6)
Trials
0
Grants
3
Labs led
1
Collaborators
89
Papers, trials and grants by year

2020: 3 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper, 1 grant · 2024: 2 papers · 2025: 3 papers · 2026: 4 papers, 2 grants

Papers 18

  1. GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.celrep.2026.117314↗
  2. Twist1 overexpression models an aggressive subtype of pancreatic ductal adenocarcinoma in vivo. Co-author DOI 10.1038/s41684-026-01729-2↗
  3. Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-2052↗
  4. Cross-species single-cell atlases chart progression, therapy-driven remodelling and immune evasion in pancreatic cancer Co-author DOI 10.64898/2026.03.19.712924↗
  5. Integrative genomic identification of therapeutic targets for pancreatic cancer. Co-author DOI 10.1016/j.celrep.2025.116191↗
  6. The Pdgfd-Pdgfrb axis orchestrates tumor-nerve crosstalk in pancreatic cancer Last author DOI 10.1101/2025.08.26.672505↗
  7. Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. Last author DOI 10.1126/sciadv.adx0632↗
  8. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Last author DOI 10.1038/s41588-024-01890-9↗
  9. Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. Co-author DOI 10.1172/jci.insight.182766↗
  10. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1046↗
  11. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer. Co-author DOI 10.1016/j.devcel.2022.04.014↗
  12. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  13. Treatment-associated remodeling of the pancreatic cancer endothelium at single-cell resolution. Last author DOI 10.3389/fonc.2022.929950↗
  14. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Co-author DOI 10.1016/j.ccell.2021.07.007↗
  15. Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. Last author DOI 10.1158/1078-0432.ccr-20-4712↗
  16. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment Co-author DOI 10.1101/2020.08.25.267336↗
  17. The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. First author DOI 10.21037/apc-2020-pda-05↗
  18. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Co-author DOI 10.3322/caac.21626↗

Grants 3

  1. Elucidating cancer-intrinsic mechanisms of perineural invasion in pancreatic cancer K08CA270417↗
  2. High Resolution Dissection of Response Mechanisms to Chemoradiation in Gastrointestinal Cancers P01CA295486↗
  3. Career Development Award: William L. Hwang (cancer-nerve dynamics in pancreatic cancer) AWARD pancan:2023-william-l-hwang-md-phd-career-development-award-william-l-hwang

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Tsai Ting · 6 shared papers, 1 shared grant, 2020–2026 · strength 1.70
  2. Theodore Sunki Hong · 4 shared papers, 1 shared grant, 2020–2026 · strength 1.41
  3. Dennis H. Gong · 6 shared papers, 2024–2026 · strength 1.20
  4. Jimmy A. Guo · 7 shared papers, 2020–2026 · strength 1.11
  5. Carina Shiau · 6 shared papers, 2022–2026 · strength 1.01
  6. Samuel Jacob Klempner · 1 shared grant, 2026 · strength 0.86
  7. Colin D. Weekes · 5 shared papers, 2020–2026 · strength 0.71
  8. Tyler Jacks · 5 shared papers, 2020–2026 · strength 0.68
  9. Mari A. Mino-Kenudson · 4 shared papers, 2020–2026 · strength 0.59
  10. Jennifer Yon-Li Wo · 4 shared papers, 2020–2025 · strength 0.55
  11. Nicholas J Caldwell · 3 shared papers, 2024–2026 · strength 0.52
  12. Ralph Weissleder · 3 shared papers, 2024–2026 · strength 0.50
  13. Andrew J. Aguirre · 3 shared papers, 2020–2026 · strength 0.48
  14. Mingjuan Lisa Zhang · 2 shared papers, 2026 · strength 0.41
  15. Julien Dilly · 2 shared papers, 2025–2026 · strength 0.41
  16. Seema Chugh · 2 shared papers, 2025–2026 · strength 0.41
  17. Lei Zheng · 2 shared papers, 2021–2026 · strength 0.36
  18. Arnav Mehta · 3 shared papers, 2020 · strength 0.36
  19. Hannah Johnson Roberts · 2 shared papers, 2024–2025 · strength 0.30
  20. Yi Cui · 1 shared paper, 2025 · strength 0.28
  21. Brian Matthew Wolpin · 1 shared paper, 2026 · strength 0.22
  22. Jonathan Andrew Nowak · 1 shared paper, 2026 · strength 0.22
  23. Carlos F. Fernandez-del Castillo · 2 shared papers, 2020–2024 · strength 0.21
  24. Christian Schneeweis · 1 shared paper, 2026 · strength 0.21
  25. Stefanie Bärthel · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.